IntelligentMDx said today that it has received US Food and Drug Administration clearance for its IMDx C. difficile for Abbott m2000 assay, a test that detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile in human stool specimens.

IMDx's analytical reactivity studies have demonstrated that its C. difficile assay is capable of detecting 31 different strains representing the global diversity of C. difficile, including NAP1 and tcdB variants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.